Weekly Roundup 5-3-13
From Eye on FDA
May 3, 2013 - 1:10pm
The grass is not greener on my side, mainly because it is mostly not there. The lawn, if you want to call it that, looks like it needs a lot of attention – probably more than I have to give … Continue reading →
May 3, 2013 - 1:10pm
Share This Article:
Pharma Buzz
- May21 1:27pmJerome "The Bus" Bettis Promotes Auvi-Q With and Without the Important Safety Information
- May21 1:24pmPlaintiff’s Second Try Still Preempted
- May21 1:20pmAstraZeneca Shakeup Of China Business Unit Steers Focus Away From Generics To Innovative Drugs
- May21 1:00pmMedWatch’s Patient-friendly Reporting Form Might Need An Overhaul
- May21 12:59pmIMRT for prostate cancer: newer, costlier radiation no better than old
- May21 12:45pmFDA’s Social Media Messages Should Be Pretested, Risk Communication Advisors Say
- May21 12:25pmExecutive Compensation as "Legal Corruption" - and the Continuing Example of the Troubles of Wake Forest Baptist
- May21 11:52amVermont passes assisted-suicide law, with drug-dispensing safeguards
- May21 11:52amImpax calls on former Teva, Watson execs to confront FDA issues
- May21 11:50amDisastrous Oklahoma Tornado Provides a Reminder of the Factors Putting People in Harm’s Way
- May21 11:46amDoes pharma spend more on marketing than R&D? A numbers check
- May21 11:17amWarnings about drug company-funded mental health websites
- May21 11:00amDon’t feel so bad, The Aging Male: It happens to lots of journals
- May21 10:59amWill U.K. watchdogs change their minds on Avastin in ovarian cancer?
- May21 10:58amNutrition 21 gets NDI for arginine silicate ingredient
- May21 10:55amJapan Pharma Annual Meeting Snapshot: Eisai, Dainippon, Shionogi, Ajinomoto, Astellas
- May21 10:51amDistrict court defends Satiereal TM for INO’Real
- May21 10:06amNovo A/S snatches up antibacterials-maker Xellia as part of new investment strategy
- May21 10:01amPaper on partially entangled states retracted for partially entangling authors
- May21 9:59amWill 2013 Be the Year of "Digital Pharma?"
- May21 9:47amWarner Chilcott CEO up for $9.2M handshake after Actavis deal
- May21 8:52amNew Asthma Drug Generates Excitement For Patients — And Its Maker
- May21 7:30amArmada 2013: Specialty Pharmacy Gets More Competitive
- May21 7:21amPromoting STEM Education, Foolishly
- May21 6:03amThe Times Publishing House threatens to sue our blogger for alleged defamation - we ain't going down without a fight!
- May21 5:29amHigh dose B vitamins help prevent Alzheimer’s, says researchers
- May21 4:15amRed blood cells harbor Pycnogenol metabolite, research shows
- May21 4:09amSystem of embargoing press releases skews perception of nutrition studies, GOED chief says
- May21 3:40amJubilant Lifesciences Orders U.S. Recall Of Acid-Reflux Indian Generic
- May21 3:35amTakeda-Lundbeck Antidepressant Shows Promise In Final U.S. Trial
- May21 3:15amToyama Chemicals Acquires Rights To New Macrolide Antibiotic Solithromycin From U.S. Firm Sempra
- May21 3:05amAbilify And Six New Drugs Push Otsuka’s 2012 Results Up 7.8%
- May21 3:05amAstraZeneca And BMS Launch First Once-Weekly Bydureon For Type 2 Diabetes In Japan
- May21 1:40amEisai President Plans Return To Growth Path With Fycompa, Halaven, Four Others
- May21 1:05amOnglyza Becomes Seventh DPP-4 Inhibitor In Japan
- May21 1:00amFarmer Faces Jail Time Over Raw Dairy Sales
- May21 1:00amDetecting Obesity Through Children’s Breath?
- May20 11:45pmHow Low Does Merck Need To Go? FDA Safety Concerns May Cut Suvorexant’s Dosing
- May20 9:30pmElan Tries To Transform With Three New Deals; Wall Street Still Skeptical
- May20 8:54pmPost America Depression
- May20 7:46pmPlaintiffs Discover Risks of Refusing to Participate in Predictive Coding Discovery
- May20 6:36pmClif Bar CEO: 'The protein trend is hot for men and women right now'
- May20 6:20pmMerger With Warner Chilcott Expected To Turn Actavis Into #3 Specialty Pharma In U.S.
- May20 6:15pmDepo-Provera Black Box Warning Challenged In Physician Petition
- May20 6:15pmPakistan Transition Government Sets Indefinite Moratorium On Drug Prices
- May20 5:55pmSince I've Been Comparing Merck To Apple -- On Repatriation -- Here's Is (Apple CEO) Tim Cook's Testimony, For Capitol Hill, This Week
- May20 4:55pmGermany’s G-BA Finds No Added Benefit For CTI’s Pixuvri, Exposing Price
- May20 2:30pmA retraction with “serious consequences to wheat production”
- May20 2:30pmAs India Finalizes New Pricing Policy, Analysts Focus On Potential Winners And Losers
- May20 12:07pmShire eyes takeover protection as bid rumors swirl, Mail says
